Insulet Corporation Reports Strong Q1 2026 Performance with Revenue Growth
Insulet Corporation reported strong financial performance for the first quarter of 2026, achieving a 30% constant currency revenue growth driven by international expansion and adoption of Omnipod 5. The company raised its full-year revenue guidance to 21%-23%, citing confidence in recurring revenue models and upcoming product integrations.
Tickers: $PODD
Topics: clinical_strategy international_expansion product_launches revenue_growth